Tenecteplase differs from alteplase in a way that allows single-bolus administration in myocardial infarction. The relevant modification is:

• A Fusion with a monoclonal antibody fragment
• B Removal of the kringle domain, abolishing fibrin binding
• C Conjugation with polyethylene glycol to prevent clearance
• D Substitution of amino acids conferring longer half-life and greater fibrin specificity ✓

Explanation

Tenecteplase is a genetically engineered alteplase variant with defined amino acid substitutions that increase fibrin specificity roughly 14-fold, increase resistance to PAI-1, and prolong the half-life from about 5 minutes to 20 minutes or more, permitting a single weight-adjusted bolus instead of an infusion. It retains the kringle domains needed for fibrin binding, and neither pegylation nor antibody fusion is involved.

Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.